Autologous CAR-T Cell Therapy Targeting CD19 or BCMA therapy (Beijing Biotech)

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameAutologous CAR-T Cell Therapy Targeting CD19 or BCMA therapy (Beijing Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulators

TargetsB-lymphocyte antigen CD19B-cell maturation protein

Therapy Area/IndicationsLupus Erythematosus, SystemicLupus Nephritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesBeijing Biotech

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech

Inactive CompaniesN/A

Active IndicationsLupus Erythematosus, SystemicLupus Nephritis

Inactive IndicationsN/A

Other Information

ATC CodeN/A